CStone Pharmaceuticals

Detailed Description

CStone Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment worldwide. The company's late-stage product pipeline includes CS1001, a monoclonal antibody against programmed death (PD) ligand 1; CS1003, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Pralsetinib, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; avapritinib, an KIT/PDGFRA inhibitor for the treatment of for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation; and ivosidenib, an IDH1 inhibitor to treat patients with IDH1 mutant relapsed or refractory acute myeloid leukemia. Its products also comprise CS1002, CS2006, CS3002, and CS3005 for solid tumors; CS5001 for solid tumors and hematologic cancers; Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma; and CS2007, CS2008, and CS500 for other indications. The company has a licensing agreement with LegoChem Biosciences to lead global development and commercialization of LCB71; and collaboration with Roche to develop and commercialize Pralsetinib for patients with RET-altered cancers. The company was incorporated in 2015 and is headquartered in Shanghai, China.